Maryland-based Novavax said Monday that its COVID-19 vaccine is 90.4% effective overall in a Phase 3 study conducted in the United States and Mexico, including 93% against predominant variants.
June 14 (UPI) — Maryland-based Novavax said Monday that its COVID-19 vaccine is 90.4% effective overall in a Phase 3 study conducted in the United States and Mexico, including 93% against predominant variants. The company said the study of 29,960 participants, which is ongoing, showed the vaccine is 91% against high-risk populations, such as the elderly and those with compromised immune systems. “Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” company CEO Stanley C.
